

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**FORM 10-Q**

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended **March 31, 2014**

Commission File Number **001-31932**

---

**CATASYS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of incorporation or organization)

**88-0464853**

(I.R.S. Employer Identification No.)

**11601 Wilshire Boulevard, Suite 950, Los Angeles, California 90025**

(Address of principal executive offices, including zip code)

**(310) 444-4300**

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer or a smaller reporting company. See definitions of "accelerated filer," "large accelerated filer," and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer  Accelerated filer  Non-accelerated filer  Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes  No

As of May 14, 2014, there were 20,693,046 shares of registrant's common stock, \$0.0001 par value, outstanding.

## TABLE OF CONTENTS

<b>PART I - FINANCIAL INFORMATION</b>	<b>3</b>
ITEM 1. Financial Statements	3
Condensed Consolidated Balance Sheets as of March 31, 2014 (unaudited) and December 31, 2013	3
Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2014 and 2013 (unaudited)	4
Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2014 and 2013 (unaudited)	5
Notes to Condensed Consolidated Financial Statements	6
ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	18
ITEM 3. Quantitative and Qualitative Disclosures About Market Risk	24
ITEM 4. Controls and Procedures	24
<b>PART II – OTHER INFORMATION</b>	<b>25</b>
ITEM 1. Legal Proceedings	25
ITEM 1A. Risk Factors	25
ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds	25
ITEM 3. Defaults Upon Senior Securities	25
ITEM 4. Mine Safety Disclosures	25
ITEM 5. Other Information	25
ITEM 6. Exhibits	25

In this report, except as otherwise stated or the context otherwise requires, the terms “we,” “us” or “our” refer to Catasys, Inc. and our wholly-owned subsidiaries. Our common stock, par value \$0.0001 per share, is referred to as “common stock.”

**PART I - FINANCIAL INFORMATION**

**Item 1. Financial Statements**

**CATASYS, INC. AND SUBSIDIARIES  
 CONDENSED CONSOLIDATED BALANCE SHEETS**

(In thousands, except for number of shares)	March 31, 2014 (unaudited)	December 31, 2013
<b>ASSETS</b>		
<b>Current assets</b>		
Cash and cash equivalents	\$ 723	\$ 1,136
Receivables, net of allowance for doubtful accounts of \$13 and \$0, respectively	293	173
Receivables from related party	-	115
Prepays and other current assets	230	275
Total current assets	1,246	1,699
<b>Long-term assets</b>		
Property and equipment, net of accumulated depreciation of \$2,014 and \$2,001, respectively	380	366
Intangible assets, net of accumulated amortization of \$406 and \$401, respectively	113	118
Deposits and other assets	353	440
<b>Total Assets</b>	<b>\$ 2,092</b>	<b>\$ 2,623</b>
<b>LIABILITIES AND STOCKHOLDERS' DEFICIT</b>		
<b>Current liabilities</b>		
Accounts payable	\$ 1,072	\$ 1,148
Accrued compensation and benefits	1,205	1,181
Deferred revenue	684	534
Other accrued liabilities	1,204	1,270
Total current liabilities	4,165	4,133
<b>Long-term liabilities</b>		
Deferred rent and other long-term liabilities	238	160
Capital leases	24	26
Warrant liabilities	13,556	16,347
<b>Total Liabilities</b>	<b>17,983</b>	<b>20,666</b>
<b>Stockholders' deficit</b>		
Preferred stock, \$0.0001 par value; 50,000,000 shares authorized; no shares issued and outstanding	-	-
Common stock, \$0.0001 par value; 500,000,000 shares authorized at March 31, 2014 and December 31, 2013, respectively; 20,559,712 and 18,835,571 shares issued and outstanding at March 31, 2014 and December 31, 2013, respectively	2	2
Additional paid-in-capital	209,182	209,169
Accumulated deficit	(225,075)	(227,214)
<b>Total Stockholders' deficit</b>	<b>(15,891)</b>	<b>(18,043)</b>
<b>Total Liabilities and Stockholders' deficit</b>	<b>\$ 2,092</b>	<b>\$ 2,623</b>

\* The financial statements have been retroactively restated to reflect the 10-for-1 reverse stock split that occurred on May 6, 2013.

See accompanying notes to the financial statements.

**CATASYS, INC. AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**  
 (unaudited)

(In thousands, except per share amounts)	Three Months Ended March 31,	
	2014	2013
<b>Revenues</b>		
Healthcare services revenues	\$ 199	\$ 99
License and management services revenues	19	36
Total revenues	\$ 218	\$ 135
<b>Operating expenses</b>		
Cost of healthcare services	\$ 333	\$ 204
General and administrative	1,505	1,629
Depreciation and amortization	28	47
Total operating expenses	\$ 1,866	\$ 1,880
<b>Loss from operations</b>	\$ (1,648)	\$ (1,745)
Interest expense	(1,312)	-
Change in fair value of warrant liability	5,101	4,360
<b>Income from operations before provision for income taxes</b>	\$ 2,141	\$ 2,615
Provision for income taxes	2	2
<b>Net Income</b>	\$ 2,139	\$ 2,613
<b>Basic and diluted net income per share:*</b>		
Basic net income per share*	\$ 0.11	\$ 0.22
<b>Basic weighted number of shares outstanding*</b>	19,449	12,057
Diluted net income per share*	\$ 0.08	\$ 0.16
<b>Diluted weighted number of shares outstanding*</b>	28,166	16,562

\* The financial statements have been retroactively restated to reflect the 10-for-1 reverse stock split that occurred on May 6, 2013.

See accompanying notes to the financial statements.

**CATASYS, INC. AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS**  
 (unaudited)

(In thousands)	Three Months Ended March 31,	
	2014	2013
<b>Operating activities:</b>		
Net income	\$ 2,139	\$ 2,613
Adjustments to reconcile net income to net cash used in operating activities:		
Depreciation and amortization	28	47
Issuance costs included in interest expense	1,311	-
Provision for doubtful accounts	13	-
Share-based compensation expense	13	68
Fair value adjustment on warrant liability	(5,101)	(4,360)
Deferred rent	78	-
Changes in current assets and liabilities:		
Receivables	(133)	(39)
Prepays and other current assets	41	47
Deferred revenue	150	38
Accounts payable and other accrued liabilities	(3)	21
Net cash used in operating activities	\$ (1,464)	\$ (1,565)
<b>Investing activities:</b>		
Deposits and other assets	\$ 87	\$ -
Purchase of property, plant, or equipment	(30)	-
Net cash provided by investing activities	\$ 57	\$ -
<b>Financing activities:</b>		
Proceeds from the issuance of common stock and warrants	\$ 1,000	\$ -
Proceeds from the exercise of warrants	-	23
Capital lease obligations	(6)	(3)
Net cash provided by financing activities	\$ 994	\$ 20
<b>Net decrease in cash and cash equivalents</b>	\$ (413)	\$ (1,545)
<b>Cash and cash equivalents at beginning of period</b>	1,136	3,153
<b>Cash and cash equivalents at end of period</b>	\$ 723	\$ 1,608
<b>Supplemental disclosure of cash paid</b>		
Income taxes	\$ 11	\$ 5
<b>Supplemental disclosure of non-cash activity</b>		
Common stock issued for exercise of warrants	\$ -	\$ 129

See accompanying notes to the financial statements.

**Catasys, Inc. and Subsidiaries**  
**Notes to Condensed Consolidated Financial Statements**  
**(unaudited)**

**Note 1. Basis of Consolidation, Presentation and Going Concern**

The accompanying unaudited interim condensed consolidated financial statements for Catasys, Inc. and our subsidiaries have been prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP") and instructions to Form 10-Q and, therefore, do not include all disclosures necessary for a complete presentation of financial position, results of operations, and cash flows in conformity with U.S. GAAP. In our opinion, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Interim results are not necessarily indicative of the results that may be expected for the entire fiscal year. The accompanying financial information should be read in conjunction with the financial statements and the notes thereto in our most recent Annual Report on Form 10-K for the year-ended December 31, 2013, from which the December 31, 2013 balance sheet has been derived.

Our financial statements have been prepared on the basis that we will continue as a going concern. At March 31, 2014, cash and cash equivalents amounted to \$723,000 and we had a working capital deficit of approximately \$2.9 million. In January 2014, we closed on a financing of approximately \$1.0 million. We have incurred significant operating losses and negative cash flows from operations since our inception. During the three months ended March 31, 2014, our cash used in operating activities amounted to \$1.5 million. We anticipate that we could continue to incur negative cash flows and net losses for the next twelve months. The financial statements do not include any adjustments relating to the recoverability of the carrying amount of the recorded assets or the amount of liabilities that might result from the outcome of this uncertainty. As of March 31, 2014, these conditions raised substantial doubt as to our ability to continue as a going concern.

Our ability to fund our ongoing operations and continue as a going concern is dependent on signing and generating fees from existing and new contracts for our Catasys managed care programs and the success of management's plans to increase revenue and continue to control expenses. We are operating our programs in Kansas, Louisiana, Massachusetts, Oklahoma, West Virginia, Kentucky, and Wisconsin. The Wisconsin program, which represents our first managed care Medicaid health plan customer, commenced enrollment in the first quarter of 2014. In 2013, we signed an agreement with a national health plan to provide services to their members in New Jersey, which we expect to commence enrollment by the end of the third quarter of 2014. We have generated fees from the launched programs and expect to increase enrollment and fees throughout 2014. However, there can be no assurance that we will generate such fees. In addition, we continue to seek ways to streamline our operating expenses.

Based on the provisions of our management services agreement ("MSA") between us and our managed professional medical corporation, we have determined that our managed professional medical corporation constitutes a variable interest entity, and that we are the primary beneficiary as defined in Financial Accounting Standards Board ("FASB") Interpretation No. 46R "Consolidation of Variable Interest Entities, an Interpretation of Accounting Research Bulletin No. 51" ("FIN 46R"). Accordingly, we are required to consolidate the revenue and expenses of our managed professional medical corporation. See Management Services Agreement heading under Note 2, Summary of Significant Accounting Policies, for more discussion.

All intercompany transactions and balances have been eliminated in consolidation.

**Note 2. Summary of Significant Accounting Policies**

**Revenue Recognition**

*Healthcare Services*

Our Catasys contracts are generally designed to provide cash fees to us on a monthly basis based on enrolled members. To the extent our contracts may include a minimum performance guarantee, we reserve a portion of the monthly fees that may be at risk until the performance measurement period is completed. To the extent we receive case rates that are not subject to the performance guarantees we recognize the case rate ratably over twelve months.

### *License and Management Services*

Our license and management services revenues are primarily derived from our managed treatment center, which we include in our consolidated financial statements, and which are derived from charging fees directly to patients for treatment and are recorded when services are provided. Revenues for other services are recognized when services are rendered.

### **Cost of Services**

#### *Healthcare Services*

Cost of healthcare services consists primarily of salaries related to our care coaches, healthcare provider claims payments, and fees charged by our third party administrators for processing these claims. Healthcare services cost of services is recognized in the period in which an eligible member receives services. We contract with doctors and licensed behavioral healthcare professionals, on a fee-for-services basis. We determine that a member has received services when we receive a claim or in the absence of a claim, by utilizing member data recorded in the OnTrak<sup>TM</sup> database within the contracted timeframe, with all required billing elements correctly completed by the service provider.

#### *License and Management Services*

Cost of license and management services primarily represents direct costs associated with providing care to patients that are incurred in connection with our managed treatment center. Costs are recognized in the periods in which medical treatment is provided. Such costs include, but are not limited to, direct labor costs, medical supplies and medications.

### **Cash Equivalents and Concentration of Credit Risk**

We consider all highly liquid investments with an original maturity of three months or less to be cash equivalents. Financial instruments that potentially subject us to a concentration of credit risk consist of cash and cash equivalents, and accounts receivable. Cash is deposited with what we believe are highly credited, quality financial institutions. The deposited cash may exceed Federal Deposit Insurance Corporation ("FDIC") insured limits. At March 31, 2014, cash and cash equivalents exceeding federal insured limits totaled \$523,710.

For the three months ended March 31, 2014, three customers accounted for approximately 68% of revenues and two customers accounted for approximately 81% of accounts receivable.

### **Basic and Diluted Income (Loss) per Share**

Basic income (loss) per share is computed by dividing the net income (loss) to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted income (loss) per share is computed by dividing the net income (loss) for the period by the weighted average number of common and dilutive common equivalent shares outstanding during the period.

Common equivalent shares, consisting of 8,717,165 and 4,505,385 incremental common shares for the three months ended March 31, 2014 and March 31, 2013, respectively, issuable upon the exercise of stock options and warrants have been included in the diluted earnings per share calculation.

(in thousands, except per share amounts)	Three Months Ended	
	March 31	
	2014	2013
<b>Numerator</b>		
Net income	\$ 2,139	\$ 2,613
<b>Denominator</b>		
Weighted-average common shares outstanding	19,449	12,057
Shares used in calculation - basic	19,449	12,057
Stock options and warrants	8,717	4,505
Shares used in calculation - diluted	28,166	16,562
<b>Net income per share</b>		
Basic	\$ 0.11	\$ 0.22
Diluted	\$ 0.08	\$ 0.16

### Share-Based Compensation

Our 2010 Stock Incentive Plan, as amended (the "Plan"), provides for the issuance of up to 1,825,000 shares of our common stock. Incentive stock options (ISOs) under Section 422A of the Internal Revenue Code and non-qualified options (NSOs) are authorized under the Plan. We have granted stock options to executive officers, employees, members of our board of directors, and certain outside consultants. The terms and conditions upon which options become exercisable vary among grants, but option rights expire no later than ten years from the date of grant and employee and board of director awards generally vest over three to five years. At March 31, 2014, we had 482,177 vested and unvested shares outstanding and 1,285,586 shares available for future awards.

Share-based compensation expense attributable to continuing operations amounted to \$13,000 and \$68,000 for the three months ended March 31, 2014, compared with the same period in 2013.

### Stock Options – Employees and Directors

We measure and recognize compensation expense for all share-based payment awards made to employees and directors based on estimated fair values on the date of grant. We estimate the fair value of share-based payment awards using the Black Scholes option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the condensed consolidated statements of operations subsequent to January 1, 2006. We account for share-based awards to employees and directors using the intrinsic value method under previous FASB rules, allowable prior to January 1, 2006. Under the intrinsic value method, no share-based compensation expense had been recognized in our consolidated statements of operations for awards to employees and directors because the exercise price of our stock options equaled the fair market value of the underlying stock at the date of grant.

Share-based compensation expense recognized for employees and directors for the three months ended March 31, 2014 and 2013, was \$12,000 and \$47,000, respectively.



Share-based compensation expense recognized in our condensed consolidated statements of operations for the three months ended March 31, 2014 and 2013, includes compensation expense for share-based payment awards granted prior to, but not yet vested, as of January 1, 2006, based on the grant date fair value estimated in accordance with the pro-forma provisions of Statement of Financial Accounting Standards (“SFAS”) 123, and for the share-based payment awards granted subsequent to January 1, 2006 based on the grant date fair value estimated in accordance with the provisions of the Accounting Standards Codification (“ASC”) 718. For share-based awards issued to employees and directors, share-based compensation is attributed to expense using the straight-line single option method. Share-based compensation expense recognized in our condensed consolidated statements of operations for the three months ended March 31, 2014 and 2013, is based on awards ultimately expected to vest, reduced for estimated forfeitures. Accounting rules for stock options require forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

During the three months ended March 31, 2014 and 2013, there were no options granted to employees. Employee and director stock option activity for the three ended March 31, 2014 are as follows:

	<b>Shares</b>	<b>Weighted Avg. Exercise Price</b>
Balance December 31, 2013	461,000	\$ 19.69
Granted	-	\$ -
Canceled	-	\$ -
Balance March 31, 2014	<u>461,000</u>	<u>\$ 19.69</u>

The expected volatility assumptions have been based on the historical and expected volatility of our stock, measured over a period generally commensurate with the expected term. The weighted average expected option term for the three months ended March 31, 2014 and 2013, reflects the application of the simplified method prescribed in SEC Staff Accounting Bulletin (“SAB”) No. 107 (and as amended by SAB 110), which defines the life as the average of the contractual term of the options and the weighted average vesting period for all option tranches.

As of March 31, 2014, there was \$33,000 of total unrecognized compensation costs related to non-vested share-based compensation arrangements granted under the Plan. That cost is expected to be recognized over a weighted-average period of approximately 0.81 years.

#### **Stock Options and Warrants – Non-employees**

We account for the issuance of options and warrants for services from non-employees by estimating the fair value of warrants issued using the Black-Scholes pricing model. This model’s calculations include the option or warrant exercise price, the market price of shares on grant date, the weighted average risk-free interest rate, the expected life of the option or warrant, and the expected volatility of our stock and the expected dividends.

For options and warrants issued as compensation to non-employees for services that are fully vested and non-forfeitable at the time of issuance, the estimated value is recorded in equity and expensed when the services are performed and benefit is received. For unvested shares, the change in fair value during the period is recognized in expense using the graded vesting method.

There were no options issued to non-employees for the three months ended March 31, 2014 or 2013. Share-based compensation expense relating to stock options and warrants recognized for non-employees was \$1,000 and \$20,000 for the three months ended March 31, 2014 and 2013, respectively.

Non-employee stock option activity for the three months ended March 31, 2014, are as follows:

	<u>Shares</u>	<u>Weighted Avg. Exercise Price</u>
Balance December 31, 2013	21,000	\$ 28.40
Canceled	-	\$ -
Balance March 31, 2014	<u>21,000</u>	<u>\$ 28.40</u>

### Common Stock

In January 2014, we entered into securities purchase agreements (the "January Agreements") with several investors, including Crede CG III, Ltd. ("Crede"), an affiliate of Terren S. Peizer, Chairman and Chief Executive Officer of the Company, relating to the sale and issuance of an aggregate of 1,724,141 shares of common stock and warrants (the "January Warrants") to purchase an aggregate of 1,724,141 shares of common stock at an exercise price of \$0.58 per share for aggregate gross proceeds of approximately \$1.0 million (the "January Offering"). The January Agreements provide that in the event that we effectuate a reverse stock split of our common stock within 24 months of the closing date of the January Offering (the "Reverse Split") and the volume weighted average price ("VWAP") of the common stock during the 20 trading days following the effective date of the Reverse Split (the "VWAP Period") declines from the closing price on the trading date immediately prior to the effective date of the Reverse Split, that we shall issue additional shares of common stock (the "Adjustment Shares").

There were no shares of common stock issued in exchange for various services or settlement of claims during the three months ended March 31, 2014 or 2013. The costs associated with shares issued for services are being amortized to share-based compensation expense on a straight-line basis over the related service periods. For the three months ended March 31, 2014 and 2013, share-based compensation expense relating to all common stock issued for consulting services was \$0 and \$1,000, respectively.

### Income Taxes

We have recorded a full valuation allowance against our otherwise recognizable deferred tax assets as of March 31, 2014. As such, we have not recorded a provision for income tax for the period ended March 31, 2014. We utilize the liability method of accounting for income taxes as set forth in ASC 740, Income Taxes. Under the liability method, deferred taxes are determined based on the temporary differences between the financial statement and tax basis of assets and liabilities using tax rates expected to be in effect during the years in which the basis differences reverse. A valuation allowance is recorded when it is more likely than not that some of the deferred tax assets will not be realized. In determining the need for valuation allowances we consider projected future taxable income and the availability of tax planning strategies. After evaluating all positive and negative historical and perspective evidences, management has determined it is more likely than not that our deferred tax assets will not be realized.

We assess our income tax positions and record tax benefits for all years subject to examination based upon our evaluation of the facts, circumstances and information available at the reporting date. For those tax positions where there is a greater than 50% likelihood that a tax benefit will be sustained, we have recorded the largest amount of tax benefit that may potentially be realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where there is less than 50% likelihood that a tax benefit will be sustained, no tax benefit has been recognized in the financial statements. Based on management's assessment of the facts, circumstances and information available, management has determined that all of the tax benefits for the period ended March 31, 2014 should be realized.

## Fair Value Measurements

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Assets and liabilities recorded at fair value in the condensed consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure fair value. The fair value hierarchy distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity's own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level I) and the lowest priority to unobservable inputs (Level III). The three levels of the fair value hierarchy are described below:

<u>Level Input:</u>	<u>Input Definition:</u>
Level I	Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.
Level II	Inputs, other than quoted prices included in Level I, that are observable for the asset or liability through corroboration with market data at the measurement date.
Level III	Unobservable inputs that reflect management's best estimate of what market participants would use in pricing the asset or liability at the measurement date.

The following table summarizes fair value measurements by level at March 31, 2014 for assets and liabilities measured at fair value:

	<u>2013</u>			
	<u>Level I</u>	<u>Level II</u>	<u>Level III</u>	<u>Total</u>
<i>(Dollars in thousands)</i>				
Certificates of deposit	\$ 87	\$ -	\$ -	\$ 87
Total assets	<u>\$ 87</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 87</u>
Warrant liabilities	\$ -	\$ -	\$ 13,556	\$ 13,556
Total liabilities	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 13,556</u>	<u>\$ 13,556</u>

Financial instruments classified as Level III in the fair value hierarchy as of March 31, 2014, represent our liabilities measured at market value on a recurring basis which include warrant liabilities resulting from recent debt and equity financings. In accordance with current accounting rules, the warrant liabilities are being marked-to-market each quarter-end until they are completely settled. The warrants are valued using the Black-Scholes option-pricing model, using both observable and unobservable inputs and assumptions consistent with those used in our estimate of fair value of employee stock options. See *Warrant Liabilities* below.

The following table summarizes our fair value measurements using significant Level III inputs, and changes therein, for the three months ended March 31, 2014:

	<u>Level III Warrant Liabilities</u>
<i>(Dollars in thousands)</i>	
Balance as of December 31, 2013	\$ 16,347
Issuance of warrants	2,310
Change in fair value	<u>(5,101)</u>
Balance as of March 31, 2014	<u>\$ 13,556</u>

## Intangible Assets

As of March 31, 2014, the gross and net carrying amounts of intangible assets that are subject to amortization are as follows:

(In thousands)	Gross Carrying Amount	Accumulated Amortization	Net Balance	Amortization Period (in years)
Intellectual property	\$ 519	\$ (406)	\$ 113	7

During the three months ended March 31, 2014, we did not acquire any new intangible assets and at March 31, 2014, all of our intangible assets consisted of intellectual property, which is not subject to renewal or extension. We had no intangible impairment for the three months ended March 31, 2014 or 2013.

Additionally, it is important to note that our overall business model, business operations and future prospects of our business have not changed materially since we performed the reviews and analysis noted above, with the exception of the timing, and annualized amounts of expected revenue.

Estimated remaining amortization expense for intangible assets for the current year and each of the next five years ending December 31 is as follows:

(In thousands) Year	Amount
2014 (9 months)	\$ 12
2015	\$ 16
2016	\$ 16
2017	\$ 16
2018	\$ 16

## Property and Equipment

Property and equipment are stated at cost, less accumulated depreciation. Additions and improvements to property and equipment are capitalized at cost. Expenditures for maintenance and repairs are charged to expense as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets, which range from two to seven years for furniture and equipment. Leasehold improvements are amortized over the lesser of the estimated useful lives of the assets or the related lease term, which is typically five to seven years.

## Variable Interest Entities

Generally, an entity is defined as a Variable Interest Entity ("VIE") under current accounting rules if it has (a) equity that is insufficient to permit the entity to finance its activities without additional subordinated financial support from other parties, or (b) equity investors that cannot make significant decisions about the entity's operations, or that do not absorb the expected losses or receive the expected returns of the entity. When determining whether an entity that is a business qualifies as a VIE, we also consider whether (i) we participated significantly in the design of the entity, (ii) we provided more than half of the total financial support to the entity, and (iii) substantially all of the activities of the VIE either involve us or are conducted on our behalf. A VIE is consolidated by its primary beneficiary, which is the party that absorbs or receives a majority of the entity's expected losses or expected residual returns.

As discussed under the heading *Management Services Agreement* below, we have an MSA with a managed medical corporation. Under this MSA, the equity owner of the affiliated medical group has only a nominal equity investment at risk, and we absorb or receive a majority of the entity's expected losses or expected residual returns. We participate significantly in the design of this MSA. We also agree to provide working capital loans to allow for the medical group to pay for its obligations. Substantially all of the activities of this managed medical corporation either involve us or are conducted for our benefit, as evidenced by the fact that under the MSA, we agree to provide and perform all non-medical management and administrative services for the medical group. Payment of our management fee is subordinate to payments of the obligations of the medical group, and repayment of the working capital loans is not guaranteed by the equity owner of the affiliated medical group or other third party. Creditors of the managed medical corporation do not have recourse to our general credit.

Based on the design and provisions of this MSA and the working capital loans provided to the medical group, we have determined that the managed medical corporation is a VIE, and that we are the primary beneficiary as defined in the current accounting rules. Accordingly, we are required to consolidate the revenues and expenses of the managed medical corporation.

#### **Management Services Agreement**

We have an executed MSA with a medical professional corporation and related treatment center. Under the MSA, we license to the treatment center the right to use our proprietary treatment programs and related trademarks and provide all required day-to-day business management services, including, but not limited to:

- general administrative support services;
- information systems;
- recordkeeping;
- scheduling;
- billing and collection;
- marketing and local business development; and
- obtaining and maintaining all federal, state and local licenses, certifications and regulatory permits.

The treatment center retains the sole right and obligation to provide medical services to its patients and to make other medically related decisions, such as the choice of medical professionals to hire or medical equipment to acquire and the ordering of drugs.

In addition, we provide office space to the treatment center on a non-exclusive basis, and we are responsible for all costs associated with rent and utilities. The treatment center pays us a monthly fee equal to the aggregate amount of (a) our costs of providing management services (including reasonable overhead allocable to the delivery of our services and including salaries, rent, equipment, and tenant improvements incurred for the benefit of the medical group, provided that any capitalized costs will be amortized over a five-year period), (b) 10%-15% of the foregoing costs, and (c) any performance bonus amount, as determined by the treatment center at its sole discretion. The treatment center's payment of our fee is subordinate to payment of the treatment center's obligations, including physician fees and medical group employee compensation.

We have also agreed to provide a credit facility to the treatment center to be available as a working capital loan, with interest at the Prime Rate plus 2%. Funds are advanced pursuant to the terms of the MSA described above. The notes are due on demand or upon termination of the MSA. At March 31, 2014, there was one outstanding credit facility under which \$13.3 million was outstanding. Our maximum exposure to loss could exceed this amount, and cannot be quantified as it is contingent upon the amount of losses incurred by the treatment center that we are required to fund under the credit facility.

Under the MSA, the equity owner of the affiliated treatment center has only a nominal equity investment at risk, and we absorb or receive a majority of the entity's expected losses or expected residual returns. We also agree to provide working capital loans to allow for the treatment center to pay for its obligations. Substantially all of the activities of the managed medical corporation either involves us or are conducted for our benefit, as evidenced by the facts that (i) the operations of the managed medical corporation is conducted primarily using our licensed protocols and (ii) under the MSA, we agree to provide and perform all non-medical management and administrative services for the treatment center. Payment of our management fee is subordinate to payments of the obligations of the treatment center, and repayment of the working capital loans is not guaranteed by the equity owner of the affiliated treatment center or other third party. Creditors of the managed medical corporation do not have recourse to our general credit. Based on these facts, we have determined that the managed medical corporation is a VIE and that we are the primary beneficiary as defined in current accounting rules. Accordingly, we are required to consolidate the assets, liabilities, revenues and expenses of the managed treatment center.

The amounts and classification of assets and liabilities of the VIE included in our consolidated balance sheets as of March 31, 2014 and December 31, 2013, are as follows:

<i>(in thousands)</i>	<b>March 31,</b>	<b>(audited) December 31,</b>
	<b>2014</b>	<b>2013</b>
Cash and cash equivalents	\$ 8	\$ 24
Receivables, net	12	24
<b>Total assets</b>	<b>\$ 20</b>	<b>\$ 48</b>
Accounts payable	13	25
Note payable to Catasys, Inc.	13,316	13,119
<b>Total liabilities</b>	<b>\$ 13,329</b>	<b>\$ 13,144</b>

#### **Warrant Liabilities**

In January 2014, we entered into the January Agreements with several investors relating to the sale and issuance of an aggregate of 1,724,141 shares of common stock and warrants to purchase an aggregate of 1,724,141 shares of common stock at an exercise price of \$0.58 per share for aggregate gross proceeds of approximately \$1.0 million. The January Agreements provide that in the event that we effectuate a Reverse Split and the VWAP period declines from the closing price on the trading date immediately prior to the effective date of the Reverse Split, that we shall issue the Adjustment Shares.

The January Warrants expire in January 2019, and contain anti-dilution provisions. As a result, if we, in the future, issue or grant any rights to purchase any of our common stock, or other securities convertible into our common stock, for a per share price less than the exercise price of the January Warrants, the exercise price of the January Warrants will be reduced to such lower price, subject to customary exceptions. In the event that Adjustment Shares are issued, the number of shares that may be purchased under the January Warrants shall be increased by an amount equal to the Adjustment Shares. In addition, the exercise price is subject to adjustment in the event that the VWAP during the VWAP period is less than the exercise price prior to the VWAP Period.

We have issued warrants to purchase common stock in July 2010, October 2010, November 2010, December 2011, February 2012, April 2012, May 2012, September 2012, December 2012, April 2013, October 2013, January 2014, and when we amended and restated the Highbridge senior secured note in July 2008. The warrants are being accounted for as liabilities in accordance with FASB accounting rules, due to provisions in some warrants that protect the holders from declines in our stock price and a requirement to deliver registered shares upon exercise of the warrants, which is considered outside our control. The warrants are marked-to-market each reporting period, using the Black-Scholes pricing model, until they are completely settled or expire.

For the three months ended March 31, 2014 and 2013, we recognized a gain of \$5.1 million and \$4.4 million, respectively, related to the revaluation of our warrant liabilities.

#### **Recently Issued or Newly Adopted Accounting Standards**

In February 2013, the FASB issued ASU 2013-02, *Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income*, (“ASU 2013-02”). ASU 2013-02 amends ASC 220, *Comprehensive Income* (“ASC 220”), and requires entities to present the changes in the components of accumulated other comprehensive income for the current period. Entities are required to present separately the amount of the change that is due to reclassifications, and the amount that is due to current period other comprehensive income. These changes are permitted to be shown either before or net-of-tax and can be displayed either on the face of the financial statements or in the footnotes. ASU 2013-02 was effective for our interim and annual periods beginning January 1, 2013. The adoption of ASU 2013-02 did not have a material effect on our consolidated financial position or results of operations.

In July 2013, the FASB issued ASU 2013-11, *Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists*, (“ASU 2013-11”), which eliminates diversity in practice for the presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss or a tax credit carryforward is available to reduce the taxable income or tax payable that would result from disallowance of a tax position. ASU 2013-11 affects only the presentation of such amounts in an entity’s balance sheet and is effective for fiscal years beginning after December 15, 2013 and interim periods within those years. The adoption of ASU 2013-11 did not have a material effect on our consolidated financial position or results of operations.

### Note 3. Segment Information

We manage and report our operations through two business segments: healthcare services and license and management services. We evaluate segment performance based on total assets, revenue and income or loss before provision for income taxes. Our assets are included within each discrete reporting segment. In the event that any services are provided to one reporting segment by the other, the transactions are valued at the market price. No such services were provided during the three months ended March 31, 2014 and 2013. Summary financial information for our two reportable segments are as follows:

(in thousands)	Three Months Ended	
	March 31,	
	2014	2013
<b>Healthcare services</b>		
Revenues	\$ 199	\$ 99
Income before provision for income taxes	2,362	2,862
Assets *	1,968	2,291
<b>License and management services</b>		
Revenues	\$ 19	\$ 36
Loss before provision for income taxes	(221)	(247)
Assets *	124	1,042
<b>Consolidated continuing operations</b>		
Revenues	\$ 218	\$ 135
Income before provision for income taxes	2,141	2,615
Assets *	2,092	3,333

\* Assets are reported as of March 31.

#### Healthcare Services

Catasys' integrated substance dependence solutions combine innovative medical and psychosocial treatments with elements of traditional disease management, case management and ongoing member support to help organizations treat and manage substance dependent populations to impact both the medical and behavioral health costs associated with substance dependence and the related co-morbidities.

We are currently marketing our integrated substance dependence solutions to managed care health plans on a case rate, monthly fee, or fee-for-service basis, which involves educating third party payors on the disproportionately high cost of their substance dependent population and demonstrating the potential for improved clinical outcomes and reduced cost associated with using our Catasys programs. We are operating our programs in Kansas, Massachusetts, Louisiana, Oklahoma, Kentucky, West Virginia, and Wisconsin. In 2013, we signed an agreement with national health plans to provide services to their members in New Jersey, and expect to commence enrollment by the end of the third quarter of 2014.

The following table summarizes the operating results for Healthcare Services for the three months ended March 31, 2014 and 2013:

(in thousands)	Three Months Ended March 31,	
	2014	2013
<b>Revenues</b>	\$ 199	\$ 99
<b>Operating Expenses</b>		
Cost of healthcare services	\$ 265	\$ 144
General and administrative expenses		
Salaries and benefits	873	1,013
Other expenses	464	435
Depreciation and amortization	24	5
Total operating expenses	\$ 1,626	\$ 1,597
<b>Loss from operations</b>	\$ (1,427)	\$ (1,498)
Interest expense	(1,312)	-
Change in fair value of warrant liabilities	5,101	4,360
<b>Income before provision for income taxes</b>	\$ 2,362	\$ 2,862

#### License and Management Services

Our license and management services segment primarily represents our managed treatment office, which offers a range of addiction treatment and mental health services.

The following table summarizes the operating results for License and Management Services for the three months ended March 31, 2014 and 2013:

(In thousands)	Three Months Ended March 31,	
	2014	2013
<b>Revenues</b>	\$ 19	\$ 36
<b>Operating expenses</b>		
Cost of license and management services	\$ 68	\$ 60
General and administrative expenses		
Salaries and benefits	96	125
Other expenses	72	57
Depreciation and amortization	4	41
Total operating expenses	\$ 240	\$ 283
<b>Loss from operations</b>	\$ (221)	\$ (247)
Interest and other income	-	-
Interest expense	-	-
<b>Loss before provision for income taxes</b>	\$ (221)	\$ (247)



#### **Note 4. Related Party Disclosure**

In December 2010, we entered into a three-year sublease agreement with Xoftek, Inc., an affiliate of our Chairman and Chief Executive Officer, to sublease approximately one-third of our office space for a three-year term for a monthly rent of approximately \$11,000 per month. The related party receivable as of March 31, 2014 and December 31, 2013 was \$0 and \$115,000, respectively. This is net of an offset of \$115,000 and \$186,000 payable to our Chairman and Chief Executive Officer against this receivable at March 31, 2014 and December 31, 2013, respectively. We have offset approximately \$382,000 in payables due to our Chairman and Chief Executive Officer as of March 31, 2014.

Crede, an affiliate of our Chairman and Chief Executive Officer, participated in our January 2014 Offering. Crede received approximately 1,585,345 shares of our common stock and warrants to purchase an aggregate 1,585,345 shares of common stock at a price of \$0.58 per share, for gross proceeds of approximately \$919,500.

#### **Note 5. Restatement of Financial Statements**

The financial statements have been retroactively restated to reflect the 10-for-1 reverse stock split that occurred on May 6, 2013.

#### **Note 6. Subsequent Events**

Beginning April 1, 2014, we agreed with the professional medical corporation to close the practice covered by the MSA.

We and our Chief Executive Officer were party to a litigation in which the plaintiffs asserted causes of action for conversion, a request for an order to set aside fraudulent conveyance and breach of contract. The litigation and subsequent appeals were resolved in our favor. The plaintiff filed a petition for review with the California Supreme Court, which was denied in April 2014. The litigation is now ended with a complete victory by the defendants.

## **Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

*The following discussion of our financial condition and results of operations should be read in conjunction with our financial statements including the related notes, and the other financial information included in this report.*

### **CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING INFORMATION**

This report contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to the financial condition, results of operations, business strategies, operating efficiencies or synergies, competitive positions, growth opportunities for existing products, plans and objectives of management, markets for stock of Catasys and other matters. Statements in this report that are not historical facts are hereby identified as “forward-looking statements” for the purpose of the safe harbor provided by Section 21E of the Exchange Act of 1934 and Section 27A of the Securities Act of 1933. Such forward-looking statements, including, without limitation, those relating to the future business prospects, our revenue and income, wherever they occur, are necessarily estimates reflecting the best judgment of our senior management as of the date on which they were made, or if no date is stated, as of the date of this report. These forward-looking statements are subject to risks, uncertainties and assumptions, including those described in the “Risk Factors” in Item 1A of Part I of our most recent Annual Report on Form 10-K (“Form 10-K”) for the fiscal year ended December 31, 2013 and other reports we filed with the Securities and Exchange Commission (“SEC”), that may affect the operations, performance, development and results of our business. Because the factors discussed in this report could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any such forward-looking statements. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We assume no obligation and do not intend to update these forward looking statements, except as required by law.

### **OVERVIEW**

#### **General**

We are a healthcare services company, providing specialized health services designed to assist health plans and other third party payors to manage and treat their high cost substance dependence members through a network of healthcare providers and our employees. The *OnTrak* program was designed to address substance dependence as a chronic disease. The program seeks to lower costs and improve member health through the delivery of integrated medical and psychosocial interventions in combination with long term “care coaching.” We also have a company managed psychiatry practice that offers a variety of mental health and substance dependence treatments primarily on a fee-for-service basis which we decided to discontinue effective April 1, 2014.

#### **Operations**

In the first quarter of 2014 we are operating our integrated substance dependence solutions for third-party payors in Kansas, Louisiana, Massachusetts, Oklahoma, Kentucky, West Virginia, and Wisconsin. In 2013, we signed a national agreement with a national health plan to provide the *OnTrak* program to their commercial members starting in New Jersey and we expect to commence enrollment by the end of the third quarter of 2014. However as our customers control significant portions of implementation, there are no assurances that commencement will not be delayed. We believe that our Catasys offerings address a high cost segment of the healthcare market for substance dependence, and we are currently marketing our Catasys integrated substance dependence solutions to managed care health plans on a case rate, monthly fee, or fee-for-service basis, which involves educating third party payors on the disproportionately high cost of their substance dependent population and demonstrating the potential for improved clinical outcomes and reduced cost associated with using our Catasys programs.

Prior to April 1, 2014, we managed, under a licensing agreement, one professional medical corporation (dba The Center to Overcome Addiction). We managed the business components of the professional medical corporation and license a proprietary treatment program in exchange for management and licensing fees under the terms of full business service management agreements. The professional medical corporation offered medical and psychosocial interventions for substance dependencies and mental health disorders. The revenues and expenses of this center are included in our consolidated financial statements under accounting standards applicable to variable interest entities. Effective April 1, 2014, we have agreed with the professional medical corporation to close the practice.

## RESULTS OF OPERATIONS

### Table of Summary Consolidated Financial Information

The table below and the discussion that follows summarizes our results of consolidated operations for the three months ended March 31, 2014 and 2013:

(In thousands, except per share amounts)	Three Months Ended	
	March 31,	
	2014	2013
<b>Revenues</b>		
Healthcare services revenues	\$ 199	\$ 99
License and management services revenues	19	36
Total revenues	\$ 218	\$ 135
<b>Operating expenses</b>		
Cost of healthcare services	\$ 333	\$ 204
General and administrative	1,505	1,629
Depreciation and amortization	28	47
Total operating expenses	\$ 1,866	\$ 1,880
<b>Loss from operations</b>	\$ (1,648)	\$ (1,745)
Interest expense	(1,312)	-
Change in fair value of warrant liability	5,101	4,360
<b>Income from operations before provision for income taxes</b>	\$ 2,141	\$ 2,615
Provision for income taxes	2	2
<b>Net Income</b>	\$ 2,139	\$ 2,613
<b>Basic and diluted net income per share:*</b>		
Basic net income per share*	\$ 0.11	\$ 0.22
<b>Basic weighted number of shares outstanding*</b>	19,449	12,057
Diluted net income per share*	\$ 0.08	\$ 0.16
<b>Diluted weighted number of shares outstanding*</b>	28,166	16,562

\* The financial statements have been retroactively restated to reflect the 10-for-1 reverse stock split that occurred on May 6, 2013.

### Summary of Consolidated Operating Results

We had net income from continuing operations before provision for income taxes of \$2.1 million and \$2.6 million for the three months ended March 31, 2014 and 2013, respectively. The difference primarily relates to the increase in interest expense of \$1.3 million for the period ended March 31, 2014 compared with the same period in 2013, offset by an increase in the change in fair value of warrant liabilities of \$741,000 during the same period.

### *Revenues*

As of March 31, 2014, six healthcare services contracts were operational resulting in a significant increase in the number of patients being treated during the same period in 2013. Recognized revenue increased by \$100,000, or 101% for the period ended March 31, 2014, compared with the same period in 2013. Most of the revenue related to these contracts are initially recorded to deferred revenue as the revenue is subject to performance guarantees, or in the case of case rates received upon enrollment, recognized ratably over the period of enrollment. Deferred revenue was \$684,000 and \$534,000 as of March 31, 2014 and December 31, 2013, respectively, which if we were able to recognize would have increased revenue by \$250,000, or 40%, compared with December 31, 2013.

Revenues decreased by \$17,000 for the license and management services segment, for the three months March 31, 2014, compared with the same periods in 2013 due to a decrease in number of patient visits at the managed physician practice. We have discontinued the operations of the Center to Overcome Addiction effective April 1, 2014.

### *Cost of Healthcare Services*

Cost of healthcare services consists primarily of salaries related to our care coaches, healthcare provider claims payments to our network of physicians and psychologists, and fees charged by our third party administrators for processing these claims. The increase of \$129,000 for the three months ended March 31, 2014, compared with the same period in 2013, relates primarily to the increase in members being treated, the mix in members treated, and the addition of more care coaches to our staff to manage the increasing number of enrolled members.

### *General and Administrative Expenses*

Total general and administrative expense decreased by \$124,000 for the three months ended March 31, 2014, compared with the same period in 2013. The decrease was due primarily to a reduction in salaries and benefits expense as a result of a majority of our stock options becoming fully vested during 2013 with no new options being granted, and a reduction in investor relations fees.

### *Impairment Losses*

There was no impairment loss related to property plant and equipment or intellectual property for the three months ended March 31, 2014 and 2013.

### *Interest Expense*

Interest expense increased by \$1.3 million for the three months ended March 31, 2014 compared with the same period in 2014 due to the issuance of warrants as part of our January 2014 financing.

### *Change in fair value of warrant liability*

We issued warrants to purchase common stock in July 2010, October 2010, November 2010, December 2011, February 2012, April 2012, May 2012, September 2012, December 2012, April 2013, October 2013, January 2014, and when we amended and restated the Highbridge senior secured note in July 2008. The warrants are being accounted for as liabilities in accordance with Financial Accounting Standards Board ("FASB") accounting rules, due to provisions in some warrants that protect the holders from declines in our stock price and a requirement to deliver registered shares upon exercise of the warrants, which is considered outside our control. The warrants are marked-to-market each reporting period, using the Black-Scholes pricing model, until they are completely settled or expire.

The change in fair value of the warrants resulted in a net gain of \$5.1 million for the three months ended March 31, 2014, compared with a net gain of \$4.4 million for the same period in 2013.

We will continue to mark the warrants to market value each quarter-end until they are completely settled.

### *Depreciation and Amortization*

Depreciation and amortization was immaterial for the three months ended March 31, 2014 and 2013, respectively.

## **LIQUIDITY AND CAPITAL RESOURCES**

### *Liquidity and Going Concern*

As of May 14, 2014, we had a balance of approximately \$352,000 cash on hand. We had working capital deficit of approximately \$2.9 million at March 31, 2014. We have incurred significant operating losses and negative operating cash flows since our inception. We could continue to incur negative cash flows and operating losses for the next twelve months. Our current cash burn rate is approximately \$500,000 per month, excluding non-current accrued liability payments. We expect our current cash resources to cover expenses until the end of May 2014, however delays in cash collections, revenue, or unforeseen expenditures, could impact this estimate. We are in need of additional capital and while we are currently in discussions with our existing stockholders regarding additional financing there is no assurance that additional capital can be raised in an amount which is sufficient for us or on terms favorable to us and our stockholders, if at all. If we do not obtain additional capital, there is a significant doubt as to whether we can continue to operate as a going concern and we will need to curtail or cease operations or seek bankruptcy relief. If we discontinue operations, we may not have sufficient funds to pay any amounts to stockholders.

In January 2014, we entered into securities purchase agreements with several investors, including Crede CG III, Ltd., an affiliate of Terren S. Peizer, Chairman and Chief Executive Officer of the Company, relating to the sale and issuance of an aggregate of 1,724,141 shares of common stock, and warrants (the "January Warrants") to purchase an aggregate of 1,724,141 shares of Common Stock at an exercise price of \$0.58 per share for aggregate gross proceeds of approximately \$1,000,000. The January Warrants expire in January 2019, and contain anti-dilution provisions. As a result, if we, in the future, issue or grant any rights to purchase any of our Common Stock, or other security convertible into our Common Stock, for a per share price less than the exercise price of the January Warrants, the exercise price of the January Warrants will be reduced to such lower price, subject to customary exceptions.

Our ability to fund our ongoing operations and continue as a going concern is dependent on signing and generating fees from existing and new contracts for our Catasys managed care programs and the success of management's plans to increase revenue and continue to control expenses. We are operating programs in Kansas, Massachusetts, Oklahoma, Louisiana, Kentucky, West Virginia, and Wisconsin. We commenced enrollment of the Wisconsin program during the first quarter of 2014, which represents our first managed care Medicaid health plan customer. In 2013, we signed an agreement with a national health plan to provide services to their members in New Jersey, which we expect to commence enrollment during the third quarter of 2014. We have generated fees from the launched programs and expect to increase enrollment and fees throughout 2014. However, there can be no assurance that we will generate such fees. In addition, we continue to seek ways to streamline our operating expenses.

Over the last two years, management took actions that have resulted in reduced annual operating expenses. These reductions have been offset by increased expenditures related to contract implementations and expanding enrollment in our programs. We anticipate increasing the number of personnel and incurring additional operating costs throughout 2014 to service our contracts as they become operational and the number of people enrolled in our program increases.

### *Cash Flows*

We used \$1.5 million of cash for continuing operating activities during the three months March 31, 2014 compared with \$1.6 million in 2013. Significant non-cash adjustments to operating activities for the three months ended March 31, 2014 included share-based compensation expense of \$13,000, depreciation and amortization of \$28,000, equity issuance costs of \$1.3 million, and a fair value adjustment on warrant liability of \$5.1 million.

Capital expenditures for the three months ended March 31, 2014 were not material. Our future capital expenditure requirements will depend upon many factors, including progress with expanding the adoption of our programs, and our marketing efforts, the necessity of, and time and costs involved in obtaining, regulatory approvals, competing technological and market developments, and our ability to establish collaborative arrangements, effective commercialization, marketing activities and other arrangements.

Our net cash provided by financing activities was \$994,000 for three months ended March 31, 2014, compared with net cash provided by financing activities of \$20,000 for the three months ended March 31, 2013. Cash provided by financing activities for the three months ended March 31, 2014 consisted of the net proceeds from the securities offerings in January 2014, leaving a balance of \$723,000 in cash and cash equivalents at March 31, 2014.

#### **OFF BALANCE SHEET ARRANGEMENTS**

As of March 31, 2014, we had no off-balance sheet arrangements.

#### **CRITICAL ACCOUNTING ESTIMATES**

The discussion and analysis of our financial condition and results of operations is based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). U.S. GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities. We base our estimates on experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that may not be readily apparent from other sources. On an on-going basis, we evaluate the appropriateness of our estimates and we maintain a thorough process to review the application of our accounting policies. Our actual results may differ from these estimates.

We consider our critical accounting estimates to be those that (1) involve significant judgments and uncertainties, (2) require estimates that are more difficult for management to determine, and (3) may produce materially different results when using different assumptions. We have discussed these critical accounting estimates, the basis for their underlying assumptions and estimates and the nature of our related disclosures herein with the audit committee of our Board of Directors. We believe our accounting policies specific to the fair value of warrants, share-based compensation expense, and the impairment assessment for intangible assets, involve our most significant judgments and estimates that are material to our consolidated financial statements. They are discussed further below.

##### *Warrant Liabilities*

We issued warrants to purchase common stock in July 2010, October 2010, November 2010, December 2011, February 2012, April 2012, May 2012, September 2012, December 2012, April 2013, October 2013, January 2014, and when we amended and restated the Highbridge senior secured note in July 2008. The warrants are being accounted for as liabilities in accordance with FASB accounting rules, due to provisions in some warrants that protect the holders from declines in our stock price and a requirement to deliver registered shares upon exercise of the warrants, which is considered outside our control. The warrants are marked-to-market each reporting period, using the Black-Scholes pricing model, until they are completely settled or expire.

For the three months ended March 31, 2014 and 2013, we recognized a gain of \$5.1 million and \$4.4 million, respectively, related to the revaluation of our warrant liabilities.

##### *Share-based compensation expense*

We account for the issuance of stock, stock options, and warrants for services from non-employees based on an estimate of the fair value of options and warrants issued using the Black-Scholes pricing model. This model's calculations include the exercise price, the market price of shares on grant date, weighted average assumptions for risk-free interest rates, expected life of the option or warrant, expected volatility of our stock and expected dividend yield.

The amounts recorded in the financial statements for share-based compensation expense could vary significantly if we were to use different assumptions. For example, the assumptions we have made for the expected volatility of our stock price have been based on the historical volatility of our stock, measured over a period generally commensurate with the expected term. If we were to use a different volatility than the actual volatility of our stock price, there may be a significant variance in the amounts of share-based compensation expense from the amounts reported. The weighted average expected option term for the three months ended March 31, 2014 and 2013, reflects the application of the simplified method set out in SEC Staff Accounting Bulletin No. 107, which defines the life as the average of the contractual term of the options and the weighted average vesting period for all option tranches.

From time to time, we have retained terminated employees as part-time consultants upon their resignation from the Company. Because the employees continue to provide services to us, their options continue to vest in accordance with the original terms. Due to the change in classification of the option awards, the options are considered modified at the date of termination. The modifications are treated as exchanges of the original awards in return for the issuance of new awards. At the date of termination, the unvested options are no longer accounted for as employee awards and are accounted for as new non-employee awards. The accounting for the portion of the total grants that have already vested and have been previously expensed as equity awards is not changed. There were no employees moved to consulting status for the three months ended March 31, 2014 and 2013, respectively.

#### *Impairment of Intangible Assets*

We have capitalized significant costs for acquiring patents and other intellectual property directly related to our products and services. We review our intangible assets for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. In reviewing for impairment, we compare the carrying value of such assets to the estimated undiscounted future cash flows expected from the use of the assets and/or their eventual disposition. If the estimated undiscounted future cash flows are less than their carrying amount, we record an impairment loss to recognize a loss for the difference between the assets' fair value and their carrying value. Since we have not recognized significant revenue to date, our estimates of future revenue may not be realized and the net realizable value of our capitalized costs of intellectual property or other intangible assets may become impaired.

During the three months March 31, 2014, we did not acquire any new intangible assets and at March 31, 2014, all of our intangible assets consisted of intellectual property, which is not subject to renewal or extension. We had no intangible impairment for the three months ended March 31, 2014 or 2013.

#### **RECENT ACCOUNTING PRONOUNCEMENTS**

In February 2013, the FASB issued ASU 2013-02, *Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income*, ("ASU 2013-02"). ASU 2013-02 amends ASC 220, *Comprehensive Income* ("ASC 220"), and requires entities to present the changes in the components of accumulated other comprehensive income for the current period. Entities are required to present separately the amount of the change that is due to reclassifications, and the amount that is due to current period other comprehensive income. These changes are permitted to be shown either before or net-of-tax and can be displayed either on the face of the financial statements or in the footnotes. ASU 2013-02 was effective for our interim and annual periods beginning January 1, 2013. The adoption of ASU 2013-02 did not have a material effect on our consolidated financial position or results of operations.

In July 2013, the FASB issued ASU 2013-11, *Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists*, ("ASU 2013-11"), which eliminates diversity in practice for the presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss or a tax credit carryforward is available to reduce the taxable income or tax payable that would result from disallowance of a tax position. ASU 2013-11 affects only the presentation of such amounts in an entity's balance sheet and is effective for fiscal years beginning after December 15, 2013 and interim periods within those years. The adoption of ASU 2013-11 did not have a material effect on our consolidated financial position or results of operations.

**Item 3. Quantitative and Qualitative Disclosures About Market Risk**

Not applicable.

**Item 4. Controls and Procedures**

**Disclosure Controls**

We have evaluated, with the participation of our principal executive officer and our principal financial officer, the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of March 31, 2014. Based on this evaluation, our principal executive officer and our principal financial officer have concluded that our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms, and is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

**Changes in Internal Control Over Financial Reporting**

There were no changes in our internal controls over financial reporting during the three months ended March 31, 2014, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.



---

---

**PART II – OTHER INFORMATION**

---

---

**Item 1. Legal Proceedings**

On February 27, 2014 the Plaintiff's filed a Petition of Review with the California Supreme Court, which was denied on April 9, 2014. The litigation is now ended with a complete victory by the defendants.

**Item 1A. Risk Factors**

There have been no material changes in our risk factors from those disclosed in our most recent Annual Report on Form 10-K.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

None.

**Item 3. Defaults Upon Senior Securities**

None.

**Item 4. Mine Safety Disclosures.**

Not applicable.

**Item 5. Other Information**

Beginning April 1, 2014, we agreed with the professional medical corporation to close the practice covered by the MSA.

**Item 6. Exhibits**

Exhibit 4.1	Form of Warrant incorporated by reference to Exhibit 4.1 of Catasys, Inc.'s Form 8-K filed with the Securities and Exchange Commission on February 3, 2014.
Exhibit 10.1	Securities Purchase Agreement between Catasys, Inc. and accredited investors incorporated by reference to Exhibit 10.1 of Catasys Inc.'s Form 8-K filed with the Securities and Exchange Commission on February 3, 2014.
Exhibit 31.1	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Exhibit 31.2	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Exhibit 32.1	Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Exhibit 32.2	Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS	XBRL Instance
101.SCH	XBRL Taxonomy Extension Schema
101.CAL	XBRL Taxonomy Extension Calculation
101.DEF	XBRL Taxonomy Extension Definition
101.LAB	XBRL Taxonomy Extension Labels
101.PRE	XBRL Taxonomy Extension Presentation

---

---

**SIGNATURES**

---

---

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CATASYS, INC.

Date: May 15, 2014

By: /s/ TERREN S. PEIZER  
Terren S. Peizer  
Chief Executive Officer  
(Principal Executive Officer)

Date: May 15, 2014

By: /s/ SUSAN ETZEL  
Susan Etzel  
Chief Financial Officer  
(Principal Financial and Accounting Officer)

**Exhibit 31.1**

**CERTIFICATION**

I, Terren S. Peizer, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Catasys, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and
  - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 15, 2014

/s/ TERREN S. PEIZER

Terren S. Peizer  
*Chief Executive Officer*  
*(Principal Executive Officer)*

**Exhibit 31.2**

**CERTIFICATION**

I, Susan Etzel, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Catasys, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and
  - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 15, 2014

/s/ SUSAN ETZEL

Susan Etzel

*Chief Financial Officer*

*(Principal Financial and Accounting Officer)*

**Exhibit 32.1**

**CERTIFICATION PURSUANT TO  
18 U.S.C. SECTION 1350,  
AS ADOPTED PURSUANT TO  
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q of Catasys, Inc. (the "Company") for the quarter ended March 31, 2014, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Terren S. Peizer, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m(a) or 78o(d)); and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ TERREN S. PEIZER

Terren S. Peizer

*Chief Executive Officer*

*(Principal Executive Officer)*

May 15, 2014

Date

**Exhibit 32.2**

**CERTIFICATION PURSUANT TO  
18 U.S.C. SECTION 1350,  
AS ADOPTED PURSUANT TO  
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q of Catasys, Inc. (the "Company") for the quarter ended March 31, 2014, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Susan Etzel, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m(a) or 78o(d)); and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ SUSAN ETZEL

Susan Etzel

*Chief Financial Officer*

*(Principal Financial and Accounting Officer)*

May 15, 2014

Date